ReviewFrontiers in immunology2022
IL-10 revisited in systemic lupus erythematosus.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 81 citations in OpenAlex.
- Review
- Whole blood exchange-lymphoplasmapheresis combined transfusion as an immunotherapy in systemic lupus erythematosus.iScience · 2026Article
- Andrographolide alleviates type 2 diabetic nephropathy through suppressing PI3K/AKT1/RRM2-triggered oxeiptosis.Journal of advanced research · 2026Article
- Interleukin-6 fromMicrobiology spectrum · 2026Article
- Potential Roles of Prostaglandins PGD2, PGJ2, and PGE2 in the Pathogenesis of Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Review
- Serum vs. tissue cytokine dysregulation in SLE-associated myocarditis: a hypothesis from an African cohort perspective.Molecular medicine (Cambridge, Mass.) · 2026Article
- Autoimmune and Inflammatory Diseases: Identifying New Advances in Immunological Insights.International journal of molecular sciences · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Basophilic exosomes promote SLE development via exacerbating B cell activation through the lncRNA ENST00000537616/miR-330-5p/KRAS axis.Journal of advanced research · 2026Article
- Serum levels of APRIL, BAFF, and IL-10 in systemic lupus erythematosus have limited utility as biomarkers for disease activity or flare prediction.Clinical rheumatology · 2026Article
- Immunological dysregulation of follicular helper T cells, follicular regulatory T cells, and follicular cytotoxic T cells is associated with disease activity and identifies exploratory immune patterns in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Gene expression profiling of dendritic cell tolerance dysfunction in women with systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Interleukin-10 at the crossroads of immunity in TLR7-induced lupus.Frontiers in immunology · 2026Article
- Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis.Frontiers in medicine · 2026Review
- Integrated metabolomic and cytokine profiling reveals biomarkers across the clinical spectrum of lupus nephritis.Frontiers in immunology · 2026Article
- Advances in Human and Animal Germinal Center Models In Vitro: New Approaches to Studying Immune Responses.BioMed research international · 2026Review
- IL-10's contextual role in cytotoxic antitumor immunity: evidence, controversies, and therapeutic translation.Frontiers in immunology · 2026Review
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- Turncoat antibodies unmasked in a model of autoimmune demyelination: From biology to therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Glycolysis inhibition functionally reprograms T follicular helper cells and reverses lupus.Cell reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-10 is a cytokine with pleiotropic functions, particularly known for its suppressive effects on various immune cells. Consequently, it can limit the pathogenesis of inflammatory diseases, such as multiple sclerosis (MS), inflammatory bowel disease, Crohn's disease, and Epidermolysis bullosa acquisita, among others. Recent evidence however indicates that it plays dual roles in Systemic lupus Erythematosus (SLE) where it may inhibit pro-inflammatory effector functions but seems to be also a main driver of the extrafollicular antibody response, outside of germinal centers (GC). In line, IL-10 promotes direct differentiation of activated B cells into plasma cells rather than stimulating a GC response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, including extrafollicular T helper cells, which are phenotypically distinct from follicular helper T cells that are relevant for GC formation. In SLE patients and murine lupus models extrafollicular T helper cells have been reported to support ongoing extrafollicular formation of autoreactive plasma cells, despite the presence of GCs. Here, we discuss the role of IL-10 as driver of B cell responses, its impact on B cell proliferation, class switch, and plasma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.